|
| [February 27, 2013] |
 |
OvaScience Presents Potential New Approach to Addressing Infertility at New York Society of Reproductive Medicine Meeting
CAMBRIDGE, Mass. --(Business Wire)--
OvaScienceSM,
(OTC: OVSC), a life sciences company focused on the discovery,
development and commercialization of new treatments for infertility,
today announced that Co-Founder Jonathan L. Tilly, Ph.D., and
Chief Executive Officer and Co-Founder Michelle Dipp, M.D., Ph.D., will
be featured speakers at the New York Society of Reproductive Medicine
(NYSRM) 2013 First Educational Meeting, being held Wednesday, February
27, 2013 in New York City.
Drs. Tilly and Dipp will give a joint presentation on a potential new
approach to treating infertility, which is based on Dr. Tilly's
discovery of egg precursor cells (EggPCSM) and is the
foundation of OvaScience's EggPC technology platform. Dr. Tilly's
lecture, titled "Bioenergetics and Egg Quality: Development of
AUGMENT to Improve IVF Outcome" will address the science that led to
the conceptual development of AUGMENTSM as a method for
improving egg quality. Dr. Dipp will follow with an overview of the
clinical of development of AUGMENT, the Company's first product
candidate that aims to improve egg quality and thereby increase the
success of in vitro fertilization (IVF).
"It is a wonderful opportunity to participate in the NYSRM lecture
series and share the work we are doing to advance the discovery of egg
precursor cells for the potential benefit of women struggling with
infertility," said Dr. Tilly, a Massachusetts Genera Hospital-based
Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard
Medical School and Affiliated Faculty Member of the Harvard Stem Cell
Institute in Boston.
About OvaScience
OvaScience (OTC: OVSC) is a life sciences company focused on the
discovery, development and commercialization of new treatments for
infertility. The Company's patented technology is based on the discovery
of egg precursor cells (EggPCSM), which are found in the
ovaries. By applying proprietary technology to identify and purify
EggPCs, AUGMENTSM aims to improve egg quality and increase
the success of in vitro fertilization (IVF). OvaScience's team of
scientists, physicians and advisers includes recognized leaders in the
field of reproductive medicine. For more information, please visit www.ovascience.com.
Forward-Looking Statements
This press release includes forward-looking statements about the
Company's strategy, future plans and prospects, including statements
regarding the development of the Company's product candidates, including
AUGMENT. Any statements in this release about our strategy, plans,
prospects and future expectations, financial position and operations,
and other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend," "may," "plan," "predict," "project,"
"target," "aim," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks
related to: our expectations regarding the regulatory approvals required
for AUGMENT; the science underlying our two product candidates, which is
unproven; our ability to obtain, maintain and protect intellectual
property utilized by our products; our ability to obtain
additional funding to support our activities; our dependence on third
parties; the successful development of, and ability to obtain regulatory
approval for, our product candidates; our ability to commercialize our
product candidates, including AUGMENT, on the timeline we expect, if at
all; competition from others; and our short operating history; as well
as those risks more fully discussed in the "Risk Factors" section of our
most recently filed Quarterly Report on Form 10-Q or Annual Report on
Form 10-K. The forward-looking statements contained in this press
release reflect our current views with respect to future events. We
anticipate that subsequent events and developments will cause our views
to change. However, while we may elect to update these forward-looking
statements in the future, we specifically disclaim any obligation to do
so. These forward-looking statements should not be relied upon as
representing our view as of any date subsequent to the date hereof.

[ Back To education 's Homepage ]
|